Skip to main content
. 2014 Aug 10;5(19):8937–8946. doi: 10.18632/oncotarget.2339

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

a. Overall survival by KRAS mutation types. b. Progression free survival of patients with KRAS and other molecular aberrations by treatment type. c. Overall survival of patients with KRAS and other molecular aberrations by treatment type. d. Overall survival of patients treated with MEK inhibitor containing trials by type of therapy